‘This is unprecedented says researcher after more than half of terminally ill blood cancer patients experienced total remission in early clinical trialsScientists are claiming “extraordinary success with engineering immune cells to target a specific type of blood cancer in their first clinical trials.
Among several dozen patients who would typically have only had months to live, early experimental trials that used the immune system’s T-cells to target cancers had “extraordinary results”.
Continue reading...
Source: theguardian.com